Bemnifosbuvir blocks hepatitis E in preclinical tests
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Bemnifosbuvir halted hepatitis E virus replication in cell cultures and animal models without damaging healthy tissue, after researchers screened roughly 500 nucleotide/nucleoside analogues to identify it
- An international team from Ruhr University Bochum, Heidelberg University Hospital, and Peking University in China published the preclinical findings in the journal Gut on March 6, 2026
- Hepatitis E infects millions worldwide and kills about 70,000 people annually, yet still has no approved vaccine or specific antiviral therapy, the researchers noted
- The compound works by mimicking the genetic building blocks of viral RNA, disrupting the virus's ability to copy itself, according to Dr. Mara Klöhn of Ruhr University Bochum
- If bemnifosbuvir's ongoing hepatitis C clinical trials succeed, Dr. Viet Loan Dao Thi and Professor Eike Steinmann said the drug could quickly become available for off-label use against hepatitis E
- HEV disproportionately endangers immunocompromised patients—including organ transplant recipients and people living with HIV—and pregnant women, in whom it can become chronic or life-threatening
Why it matters: For the 70,000 people who die from hepatitis E each year, and the millions more infected, bemnifosbuvir could become the first targeted treatment for a disease with no approved vaccine or therapy. Because the drug is already in human hepatitis C trials, the path to an off-label pivot against HEV could compress from a typical decade-long development timeline into a far shorter one for the immunocompromised and pregnant patients most at risk.
